Is Eli Lilly Stock an Undervalued Stock to Buy? | LLY Stock Discounted Cash Flow Valuation
1 extracted signal · 0 resolved · 1 still active
Parkev Tatevosian, CFA25 May 2026, 11:45 UTC
AI-generated source summary
Eli Lilly and Company (LLY) is projected to generate $90 billion in free cash flow over the next decade, driven by its weight loss treatments and innovations. The company's weighted average cost of capital (WACC) is 6.79%, and its beta is 0.585, indicating lower volatility compared to the market. The market risk premium is 6%. Using a discounted cash flow model, the present value of operations is estimated at $1,304,790,000,000 and the terminal value at $1,806,878,400,000. The value of equity is calculated at $1,277,187,609,320, resulting in an intrinsic value per share of $1,356.16. This intrinsic value is significantly higher than the current market price of $809.64, suggesting the stock is undervalued. The low beta and WACC suggest a relatively stable and low-risk investment, with expected future cash flows supporting a bullish outlook.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.